Lyell Immunopharma 2024 T-Cell Therapy Investor Presentation

Lyell Immunopharma presents its clinical pipeline of cell therapy candidates, including TIL therapies (LYL797) and next-generation ROR1-targeted CAR T cells (LYL119, LYL845) designed with anti-exhaustion technology. The company demonstrates initial Phase 1 clinical activity with 40% overall response rate and a strong balance sheet supporting runway into 2027.